

chain nodes :
 15 16 17 18 19
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14
 chain bonds :
 1-15 13-19 15-16 16-17 16-18
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
 exact/norm bonds :
 1-15 4-7 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14 13-19 15-16 16-17
 16-18
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003

NEWS 42 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 43 Feb 13 CANCERLIT is no longer being updated
NEWS 44 Feb 24 METADEX enhancements
NEWS 45 Feb 24 PCTGEN now available on STN
NEWS 46 Feb 24 TEMA now available on STN
NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 48 Feb 26 PCTFULL now contains images
NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:57:27 ON 18 MAR 2003

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:57:42 ON 18 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

DICTIONARY FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP

PROPERTIES for more information. See STNote 27, Searching Properties
in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10006215.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 13:58:06 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 306 TO ITERATE

100.0% PROCESSED 306 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5071 TO 7169

PROJECTED ANSWERS: 11 TO 389

L2 10 SEA SSS SAM L1

=> s l1

SAMPLE SEARCH INITIATED 13:58:16 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 306 TO ITERATE

100.0% PROCESSED 306 ITERATIONS

10 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 5071 TO 7169

PROJECTED ANSWERS: 11 TO 389

L3 10 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 13:58:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 6528 TO ITERATE

100.0% PROCESSED 6528 ITERATIONS
SEARCH TIME: 00.00.01

136 ANSWERS

L4 136 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.15

148.36

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2003 VOL 138 ISS 12
FILE LAST UPDATED: 17 Mar 2003 (20030317/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4


L5 5 L4

=> d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

ANSWER 1 OF 5 CAPLUS COPYRIGHT 2003 ACS

GI



AB Title compd. (I) was prepd. via reaction of 4b(S)-Benzyl-7(S)-hydroxy-7-(3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2-carboxylic acid (II) with 3-aminomethyl-2-methylpyridine (III) in the presence of carbonyldiimidazole. Thus, II (prepn. given) and carbonyldiimidazole were refluxed 2 h in THF; III in THF was added followed by stirring for 3 h at room temp. to give 69% I.

ACCESSION NUMBER: 2002:330265 CAPLUS

DOCUMENT NUMBER: 136:340594

TITLE: Preparation of 4b(S)-benzyl-7(S)-hydroxy-7-(3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2-carboxylic acid (2-methylpyridin-3-ylmethyl)amide via an amidation reaction using carbonyldiimidazole.

INVENTOR(S): Murry, Jerry Anthony; White, Timothy Donald

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 53 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201655	A2	20020502	EP 2001-309057	20011025
EP 1201655	A3	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002087005	A1	20020704	US 2001-8619	20011022
CN 1356319	A	20020703	CN 2001-135596	20011026
JP 2002193937	A2	20020710	JP 2001-329529	20011026
BR 2001004836	A	20021015	BR 2001-4836	20011029

PRIORITY APPLN. INFO.: US 2000-243873P P 20001027

OTHER SOURCE(S): CASREACT 136:340594

IT 418814-84-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of benzylhydroxytrifluoropropyloctahydrophenanthrenecarboxylic acid methylpyridinylmethylamide via an amidation reaction)

RN 418814-84-3 CAPLUS


CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2003 ACS
GI

Applicant



AB Title compds. [I; R1 = (trifluoromethyl)alkyl, CF3, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF3, CH2OA; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H, alkylamino, alkylhet; R3R4N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring contg. 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R7; R7 = (substituted) alkyl; with provisos], were prepd. for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A soln. of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-ethyl-[2R-(2.alpha.,4a.alpha.,10a.beta.)] (prepn. given), COCl2, and Et3N in THF was stirred at room temp. for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS

DOCUMENT NUMBER: 136:340495

TITLE: Preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators

INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson, Ralph Pelton, Jr.

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201649	A1	20020502	EP 2001-309064	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002193911	A2	20020710	JP 2001-328050	20011025
US 2002107235	A1	20020808	US 2001-46215	20011026
BR 2001004831	A	20020820	BR 2001-4831	20011026
PRIORITY APPLN. INFO.:			US 2000-243993P	P 20001028

OTHER SOURCE(S): MARPAT 136:340495

IT 418814-84-3P 419534-40-0P 419534-41-1P
 419534-42-2P 419534-43-3P 419534-44-4P
 419534-45-5P 419534-46-6P 419534-47-7P
 419534-48-8P 419534-49-9P 419534-50-2P
 419534-51-3P 419534-52-4P 419534-53-5P
 419534-54-6P 419534-55-7P 419534-57-9P
 419534-59-1P 419534-60-4P 419534-61-5P
 419534-62-6P 419534-63-7P 419534-64-8P
 419534-65-9P 419534-67-1P 419534-69-3P
 419534-71-7P 419534-73-9P 419534-74-0P
 419534-75-1P 419534-76-2P 419534-79-5P
 419534-80-8P 419534-83-1P 419534-85-3P
 419534-86-4P 419534-87-5P 419534-88-6P
 419534-89-7P 419534-90-0P 419534-91-1P
 419534-92-2P 419534-93-3P 419534-96-6P
 419534-97-7P 419534-98-8P 419535-00-5P
 419535-01-6P 419535-02-7P 419535-03-8P
 419535-04-9P 419535-05-0P 419535-06-1P
 419535-07-2P 419535-08-3P 419535-17-4P
 419535-20-9P 419535-22-1P 419535-24-3P
 419535-26-5P 419535-27-6P 419535-28-7P
 419535-29-8P 419535-31-2P 419535-32-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators)

RN 418814-84-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 419534-40-0 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-41-1 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-42-2 CAPLUS

CN Carbamic acid, [2-(1-piperidiny)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-43-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-44-4 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-45-5 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-46-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-47-7 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-48-8 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-49-9 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-50-2 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-51-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-52-4 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-53-5 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-54-6 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-55-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-57-9 CAPLUS

CN Carbamic acid, [3-(4-methyl-1-piperazinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-59-1 CAPLUS

CN Carbamic acid, [2-(1-piperidiny)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-60-4 CAPLUS

CN Carbamic acid, [3-(hexahydro-1H-azepin-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-61-5 CAPLUS

CN Carbamic acid, methyl(1-methyl-4-piperidiny)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-62-6 CAPLUS

CN Carbamic acid, [2-(1-piperidiny)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-

octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-63-7 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-64-8 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-65-9 CAPLUS

CN Carbamic acid, [2-(1-piperidiny)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-67-1 CAPLUS

CN Carbamic acid, [2-(1-methyl-2-pyrrolidiny)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-69-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidiny)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 419534-71-7 CAPLUS

CN Carbamic acid, [3-(6-methyl-3,6-diazabicyclo[3.1.1]hept-3-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-73-9 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-74-0 CAPLUS

CN Carbamic acid, methyl(1-methyl-3-pyrrolidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-75-1 CAPLUS

CN Carbamic acid, [(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-76-2 CAPLUS

CN Carbamic acid, [3-(2-methyl-1-piperidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-79-5 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-

4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-80-8 CAPLUS

CN Carbamic acid, [4-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)butyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-83-1 CAPLUS

CN Carbamic acid, (3S)-1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-85-3 CAPLUS

CN Carbamic acid, (3R)-1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-86-4 CAPLUS

CN Carbamic acid, 1-azabicyclo[2.2.2]oct-3-yl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-87-5 CAPLUS

CN Carbamic acid, (2-amino-2-methylpropyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-88-6 CAPLUS

CN Carbamic acid, [(1-ethyl-2-pyrrolidinyl)methyl]-, (4bS,7R,8aR)-

4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-89-7 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidiny)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-90-0 CAPLUS

CN Carbamic acid, (1-ethyl-3-piperidiny)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419534-91-1 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-

phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-92-2 CAPLUS

CN Carbamic acid, [3-(hexahydro-1H-azepin-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-93-3 CAPLUS

CN Carbamic acid, [[[2R]-1-ethyl-2-pyrrolidinyl]methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-96-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-97-7 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-98-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-00-5 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-01-6 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-02-7 CAPLUS

CN Carbamic acid, [3-(ethylmethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-03-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bS,7R,8aR)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-04-9 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]methyl-, (4bS,7R,8aR)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-05-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bS,7R,8aR)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-06-1 CAPLUS

CN Carbamic acid, [3-(1-piperidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-07-2 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-08-3 CAPLUS

CN Carbamic acid, (2,2,6,6-tetramethyl-4-piperidinyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-17-4 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-
phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-20-9 CAPLUS

CN Carbamic acid, [[[2S]-1-ethyl-2-pyrrolidinyl]methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-22-1 CAPLUS

CN Carbamic acid, [[[2R]-1-ethyl-2-pyrrolidinyl]methyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-24-3 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-26-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-27-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-28-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-29-8 CAPLUS

CN Carbamic acid, [3-(4-morpholinyl)propyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-31-2 CAPLUS


CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 419535-32-3 CAPLUS
 CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


~~LS~~ ANSWER 3 OF 5 CAPLUS COPYRIGHT 2003 ACS
 AB Comps. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER: 2001:338070 CAPLUS
 DOCUMENT NUMBER: 134:336224
 TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X
 INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi
 PATENT ASSIGNEE(S): Pfizer Products Inc., USA
 SOURCE: Eur. Pat. Appl., 55 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
PRIORITY APPLN. INFO.:		US 1999-162340P P 19991029		
OTHER SOURCE(S):		MARPAT 134:336224		
IT 305822-31-5				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)				
RN	305822-31-5 CAPLUS			
CN	Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester			

(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2003 ACS
GI



II

AB Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O' E = C, CR6, N; F = CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2, R3 = null when adjacent dashed line = bond; R4, R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7, R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14, R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepd. as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addn. with Me vinyl ketone in the presence of

(S)-(-)-.alpha.-methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone deriv. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, redn. of the enone with lithium and ammonia, addn. of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid deriv. which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:790448 CAPLUS
DOCUMENT NUMBER: 133:350060
TITLE: Preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors
INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Swick, Andrew Gordon
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 279 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066522	A1	20001109	WO 2000-IB366	20000327
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000010138	A	20020122	BR 2000-10138	20000327
EP 1175383	A1	20020130	EP 2000-911172	20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543169	T2	20021217	JP 2000-615356	20000327
US 6380223	B1	20020430	US 2000-559384	20000427
NO 2001005272	A	20011228	NO 2001-5272	20011029
US 2002147336	A1	20021010	US 2002-80174	20020219
PRIORITY APPLN. INFO.:			US 1999-132130P	P 19990430
			WO 2000-IB366	W 20000327
			US 2000-559384	A3 20000427

OTHER SOURCE(S): MARPAT 133:350060

IT 305822-26-8P 305822-28-0P 305822-29-1P
305822-30-4P 305822-31-5P 305822-32-6P
305822-33-7P 305822-34-8P 305822-35-9P
305822-36-0P 305822-37-1P 305822-38-2P
305822-39-3P 305825-20-1P 305825-21-2P
305825-22-3P 305825-44-9P 305825-45-0P
305825-46-1P 305825-48-3P 305826-86-2P
305826-91-9P 305826-93-1P 305826-98-6P
305827-03-6P 305827-05-8P 305827-06-9P
305827-08-1P 305827-11-6P 305827-14-9P


305827-29-6P 305827-30-9P 305827-43-4P
 305827-66-1P 305827-76-3P 305827-78-5P
 305827-80-9P 305827-97-8P 305827-99-0P
 305828-03-9P 305828-13-1P 305828-19-7P
 305828-21-1P 305828-30-2P 305828-37-9P
 305828-38-0P 305828-41-5P 305828-42-6P
 305829-95-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-26-8 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-28-0 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305822-29-1 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-30-4 CAPLUS

CN Carbamic acid, [3-(1H-imidazol-1-yl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-31-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-32-6 CAPLUS

CN Carbamic acid, [3-(1-pyrrolidinyl)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-33-7 CAPLUS

CN Carbamic acid, [2-(3-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-34-8 CAPLUS

CN Carbamic acid, (2-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-35-9 CAPLUS

CN Carbamic acid, [2-(2-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-36-0 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-37-1 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-38-2 CAPLUS

CN Carbamic acid, [2-(4-pyridinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305822-39-3 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-20-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-methoxy-4b-(2-methoxyethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-21-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-methoxyethyl)-2-phenanthrenyl

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-22-3 CAPLUS

CN Carbamic acid, dimethyl-, (4bS, 7R, 8aR)-7-(chloroethynyl)-4b-[2-[2-(dimethylamino)-2-oxoethoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-44-9 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR, 7R, 8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-45-0 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR, 7R, 8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305825-46-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305825-48-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305826-86-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aR)-7-(chloroethynyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA

INDEX NAME)


Absolute stereochemistry.



RN 305826-91-9 CAPLUS

CN Carbamic acid, dimethyl-, 4-[[[(4aS,10aS)-7-[[[(dimethylamino)carbonyl]oxy]-1,3,4,9,10,10a-hexahydro-2-hydroxy-2-propyl-4a(2H)-phenanthrenyl]methyl]phenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-93-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aS)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[[4-[(1-methylethyl)aminophenyl]methyl]-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305826-98-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,8aR)-4b-[[4-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-03-6 CAPLUS

CN 2,7-Phenanthrenediol, 4a-[[3-(dimethylamino)phenyl]methyl]-
1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, 7-carbamate, (4aS,10aR)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-05-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,8aR)-4b-[[3-(
(dimethylamino)phenyl]methyl)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-
propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-06-9 CAPLUS

CN Acetamide, N-[4-[[4a(4S,10aR)-7-[(aminocarbonyl)oxy]-1,3,4,9,10,10a-
hexahydro-2-hydroxy-2-(1-propynyl)-4a(2H)-phenanthrenyl]methyl]phenyl]-

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-08-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-11-6 CAPLUS

CN 2,7-Phenanthrenediol, 4a-[[3-(dimethylamino)phenyl]methyl]-1,2,3,4,4a,9,10,10a-octahydro-2-(1-propynyl)-, 7-(methylcarbamate), (2R,4aS,10aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305827-14-9 CAPLUS

CN Carbamic acid, 1H-1,2,4-triazol-3-yl-, (4bS,8aR)-4b-[[3-

(dimethylamino)phenyl)methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-29-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-30-9 CAPLUS

CN Carbamic acid, dimethyl-, (2R,4aS,10aR)-1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-(1-propynyl)-2,7-phenanthrenediyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-43-4 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305827-66-1 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b-[[4-(acetylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-76-3 CAPLUS

CN Carbamic acid, [2-(1-methyl-2-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-78-5 CAPLUS

CN Carbamic acid, 3-pyridinyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-80-9 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-propenyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-97-8 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-99-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-03-9 CAPLUS

CN Carbamic acid, (1H-tetrazol-5-ylmethyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-13-1 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-19-7 CAPLUS

CN Carbamic acid, (2-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-21-1 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 305828-30-2 CAPLUS

CN Carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)

(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-37-9 CAPLUS

CN Carbamic acid, [2-(2-pyridinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-38-0 CAPLUS

CN Carbamic acid, [2-(4-morpholinyl)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-41-5 CAPLUS

CN Carbamic acid, (4-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 305828-42-6 CAPLUS

CN Carbamic acid, (3-pyridinylmethyl)-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-pentyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 305829-95-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(ethoxymethyl)-4b,5,6,7,8,8a,9,10-

octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 305823-17-0P 305823-64-7P 305823-65-8P
 305823-66-9P 305823-67-0P 305823-68-1P
 305823-69-2P 305823-70-5P 305823-71-6P
 305823-72-7P 305823-74-9P 305823-76-1P
 305823-78-3P 305823-80-7P 305823-82-9P
 305823-84-1P 305823-86-3P 305823-88-5P
 305830-68-6P 305830-69-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305823-17-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-64-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-(4-formylphenoxy)ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-65-8 CAPLUS

CN Carbamic acid, dimethyl-, (4bS, 7R, 8aR)-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-4b-[2-[4-(4-morpholinylmethyl)phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-66-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS, 7R, 8aR)-4b-[2-[4-[(dimethylamino)methyl]phenoxy]ethyl]-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-67-0 CAPLUS

CN Carbamic acid, dimethyl-, (4bS, 7R, 8aR)-4b-[2-[4-
[(ethylamino)methyl]phenoxy]ethyl]-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-hydroxy-
7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




● HCl

RN 305823-68-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS, 7R, 8aR)-4b, 5, 6, 7, 8, 8a, 9, 10-octahydro-7-
hydroxy-4b-[2-[4-[(methylamino)methyl]phenoxy]ethyl]-7-(1-propynyl)-2-
phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-69-2 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[1-methyl(methylsulfonyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305823-70-5 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-4b-[2-[4-(1-pyrrolidinylmethyl)phenoxy]ethyl]-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-71-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[(4-methyl-1-piperazinyl)methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 305823-72-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-[[methyl(1-methyl-4-piperidinyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 305823-74-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[2-(dimethoxyethyl)amino]methyl]phenoxy]ethyl]-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-76-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[[2-(dimethylamino)ethyl]amino]methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 305823-78-3 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[[2-(dimethylamino)ethyl]methylamino]methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, hydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




●x HCl

RN 305823-80-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[[2-(diethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-82-9 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-
[(cyclopropylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-
hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-84-1 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b-[2-[4-[[bis(2-
methoxyethyl)amino]methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-
hydroxy-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-86-3 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-
 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-[2-[4-(4-
 morpholinylmethyl)phenoxy]ethyl]-2-phenanthrenyl ester, monohydrochloride
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305823-88-5 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-7-(chloroethynyl)-4b-[2-[4-
 [(dimethylamino)methyl]phenoxy]ethyl]-4b,5,6,7,8,8a,9,10-octahydro-7-
 hydroxy-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305830-68-6 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-oxoethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305830-69-7 CAPLUS

CN Carbamic acid, dimethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(2-hydroxyethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2003 ACS

AB The enhancers are selected from compds. bearing triphenylene rings and used at 0.01-20 parts per 100 parts cellulose esters to attain a retardation value (Rth550) of 70-400 nm for a wave length of 550 nm across film thickness. Thus, cast molding a dope contg. cellulose acetate (acetylation degree 60.9%) 45, a 4-methoxybenzoyloxy group-contg. triphenylene (I) 0.59, methylene chloride 232.72, MeOH 42.57 and BuOH 8.50 parts gave a 100-.mu.m film with Rth550 179 nm, vs. 20 nm in the absence of the I.

ACCESSION NUMBER: 2000:705290 CAPLUS

DOCUMENT NUMBER: 133:297278

TITLE: Retardation enhancers for films of cellulose lower fatty acid esters and their use in optical compensation sheets of liquid-crystal display devices

INVENTOR(S): Matsuoka, Koujin; Kawata, Tadashi; Murayama, Masahiko

PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 30 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2000275434	A2	20001006	JP 1999-81891	19990325
PRIORITY APPLN. INFO.:			JP 1999-81891	19990325


IT 300671-40-3

RL: POF (Polymer in formulation); PRP (Properties); TEM (Technical or engineered material use); USES (Uses)

(for films of cellulose lower fatty acid esters and use in optical compensation sheets of liq.-crystal display devices)

RN 300671-40-3 CAPLUS

CN 2,3,6,7,10,11-Triphenylenehexol, hexakis(phenylcarbamate) (9CI) (CA INDEX NAME)



=> d his

03/18/2003

Print selected from Online session

(FILE 'HOME' ENTERED AT 13:57:27 ON 18 MAR 2003)

FILE 'REGISTRY' ENTERED AT 13:57:42 ON 18 MAR 2003

L1 STRUCTURE UPLOADED



L2 10 S L1

L3 10 S L1

L4 136 S L1 FUL

FILE 'CAPLUS' ENTERED AT 13:58:34 ON 18 MAR 2003

L5 5 S L4



chain nodes :
 15 16 17 18 19 20 21
 ring nodes :
 1 2 3 4 5 6 7 8 9 10 11 12 13 14
 chain bonds :
 1-15 13-21 15-16 16-17 16-18 18-19 19-20
 ring bonds :
 1-2 1-6 2-3 3-4 4-5 4-7 5-6 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14
 exact/norm bonds :
 1-15 4-7 5-10 7-8 7-11 8-9 8-14 9-10 11-12 12-13 13-14 13-21 15-16 16-17
 16-18 18-19 19-20
 normalized bonds :
 1-2 1-6 2-3 3-4 4-5 5-6

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
 12:Atom 13:Atom 14:Atom 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
 21:CLASS

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal611hxl

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Apr 08	"Ask CAS" for self-help around the clock
NEWS	3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS	4	Apr 09	ZDB will be removed from STN
NEWS	5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS	6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS	7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS	8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS	9	Jun 03	New e-mail delivery for search results now available
NEWS	10	Jun 10	MEDLINE Reload
NEWS	11	Jun 10	PCTFULL has been reloaded
NEWS	12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS	13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS	14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS	15	Jul 30	NETFIRST to be removed from STN
NEWS	16	Aug 08	CANCERLIT reload
NEWS	17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS	18	Aug 08	NTIS has been reloaded and enhanced
NEWS	19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS	20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS	21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS	22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS	23	Sep 03	JAPIO has been reloaded and enhanced
NEWS	24	Sep 16	Experimental properties added to the REGISTRY file
NEWS	25	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS	26	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS	27	Oct 21	EVENTLINE has been reloaded
NEWS	28	Oct 24	BEILSTEIN adds new search fields
NEWS	29	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS	30	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS	31	Nov 18	DKILIT has been renamed APOLLIT
NEWS	32	Nov 25	More calculated properties added to REGISTRY
NEWS	33	Dec 02	TIBKAT will be removed from STN
NEWS	34	Dec 04	CSA files on STN
NEWS	35	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS	36	Dec 17	TOXCENTER enhanced with additional content
NEWS	37	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS	38	Dec 30	ISMEC no longer available
NEWS	39	Jan 13	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS	40	Jan 21	NUTRACEUT offering one free connect hour in February 2003
NEWS	41	Jan 21	PHARMAML offering one free connect hour in February 2003
NEWS	42	Jan 29	Simultaneous left and right truncation added to COMPENDEX,

ENERGY, INSPEC

NEWS 43 Feb 13 CANCERLIT is no longer being updated
 NEWS 44 Feb 24 METADEX enhancements
 NEWS 45 Feb 24 PCTGEN now available on STN
 NEWS 46 Feb 24 TEMA now available on STN
 NEWS 47 Feb 26 NTIS now allows simultaneous left and right truncation
 NEWS 48 Feb 26 PCTFULL now contains images
 NEWS 49 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a,
 CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),
 AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
 NEWS HOURS STN Operating Hours Plus Help Desk Availability
 NEWS INTER General Internet Information
 NEWS LOGIN Welcome Banner and News Items
 NEWS PHONE Direct Dial and Telecommunication Network Access to STN
 NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:54:19 ON 18 MAR 2003

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:54:28 ON 18 MAR 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8
 DICTIONARY FILE UPDATES: 17 MAR 2003 HIGHEST RN 499763-93-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STN Note 27, Searching Properties in the CAS Registry File, for complete details:

03/18/2003

10006215.trn

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>


Uploading 10006215.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:54:47 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 168 TO ITERATE

100.0% PROCESSED 168 ITERATIONS

3 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2583 TO 4137

PROJECTED ANSWERS: 3 TO 163

L2 3 SEA SSS SAM L1


=> d scan

03/18/2003

10006215.trn

L2 3 ANSWERS REGISTRY COPYRIGHT 2003 ACS
IN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl)methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
MF C31 H41 N3 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

03/18/2003

10006215.trn

=> s l1 ful

FULL SEARCH INITIATED 11:55:27 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3276 TO ITERATE

100.0% PROCESSED 3276 ITERATIONS
SEARCH TIME: 00.00.01

28 ANSWERS

L3 28 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

148.55

148.76

FILE 'CAPLUS' ENTERED AT 11:55:34 ON 18 MAR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Mar 2003 VOL 138 ISS 12
FILE LAST UPDATED: 17 Mar 2003 (20030317/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3

L4 4 L3

=> d abs ibib hitstr 1-

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS
GI



AB Title compd. (I) was prepd. via reaction of 4b(S)-Benzyl-7(S)-hydroxy-7-(3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2-carboxylic acid (II) with 3-aminomethyl-2-methylpyridine (III) in the presence of carbonyldiimidazole. Thus, II (prepn. given) and carbonyldiimidazole were refluxed 2 h in THF; III in THF was added followed by stirring for 3 h at room temp. to give 69% I.

ACCESSION NUMBER: 2002:330265 CAPLUS

DOCUMENT NUMBER: 136:340594

TITLE: Preparation of 4b(S)-benzyl-7(S)-hydroxy-7-(3,3,3-trifluoropropyl)-4b,5,6,7,8,8a(R)-9,10-octahydrophenanthrene-2-carboxylic acid (2-methylpyridin-3-ylmethyl)amide via an amidation reaction using carbonyldiimidazole.

INVENTOR(S): Murry, Jerry Anthony; White, Timothy Donald

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 53 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201655	A2	20020502	EP 2001-309057	20011025
EP 1201655	A3	20020626		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2002087005	A1	20020704	US 2001-8619	20011022
CN 1356319	A	20020703	CN 2001-135596	20011026
JP 2002193937	A2	20020710	JP 2001-329529	20011026
BR 2001004836	A	20021015	BR 2001-4836	20011029

PRIORITY APPLN. INFO.: US 2000-243873P P 20001027

OTHER SOURCE(S): CASREACT 136:340594

IT 418814-84-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of benzylhydroxytrifluoropropyloctahydrophenanthrenecarboxylic acid methylpyridinylmethyleamide via an amidation reaction)


03/18/2003

10006215.trn


RN 418814-84-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-
4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS
GI



AB Title compds. [I; R1 = (trifluoromethyl)alkyl, CF₃, C.tplbond.CMe, C.tplbond.CCl, C.tplbond.CCF₃, CH₂OA; A = (trifluoromethyl)alkyl; R2 = alkyl, alkenyl, (substituted) Ph; R3 = H, alkyl, haloalkyl, alkenyl, alkynyl, haloalkynyl; R4 = H, alkylamino, alkylhet; R3R4N = het; het = (substituted) 5-7 membered (unsatd.) heterocyclic ring contg. 1-3 of N, O, S; and including any bicyclic group in which any of the above heterocyclic rings is fused to a benzene ring or another heterocyclic ring; and optionally substituted with 1-4 R7; R7 = (substituted) alkyl; with provisos], were prepd. for treatment of obesity, diabetes, depression, anxiety, neurodegeneration, and inflammatory disease (no data). A soln. of 2,7-phenanthrenediol, 1,2,3,4,4a,9,10,10a-octahydro-4a-(phenylmethyl)-2-ethyl-[2R-(2.alpha.,4a.alpha.,10a.beta.)] (prepn. given), COCl₂, and Et₃N in THF was stirred at room temp. for 3 h; 1-(2-aminoethyl)pyrrolidine was added followed by stirring overnight to give 41% carbamic acid, [2-(1-pyrrolidinyl)ethyl]-, (4bS,7R,8aR)-7-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl ester.

ACCESSION NUMBER: 2002:330263 CAPLUS
DOCUMENT NUMBER: 136:340495
TITLE: Preparation of octahydrophenanthrenyl carbamates as glucocorticoid receptor modulators
INVENTOR(S): Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Robinson, Ralph Pelton, Jr.
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: Eur. Pat. Appl., 42 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1201649	A1	20020502	EP 2001-309064	20011025
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002193911	A2	20020710	JP 2001-328050	20011025
US 2002107235	A1	20020808	US 2001-6215	20011026
BR 2001004831	A	20020820	BR 2001-4831	20011026
PRIORITY APPLN. INFO.:			US 2000-243993P	P 20001028
OTHER SOURCE(S): MARPAT 136:340495				
IT 418814-84-3P 419534-43-3P 419534-46-6P				
419534-55-7P 419534-64-8P 419534-87-5P				
419534-91-1P 419534-96-6P 419534-97-7P				

419534-98-8P 419535-00-5P 419535-01-6P
 419535-02-7P 419535-03-8P 419535-04-9P
 419535-05-0P 419535-07-2P 419535-24-3P
 419535-26-5P 419535-27-6P 419535-28-7P



RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(prepn. of octahydrophenanthrenyl carbamates as glucocorticoid receptor
 modulators)

RN 418814-84-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-
 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-
 (trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-43-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-7-(ethoxymethyl)-
 4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-2-phenanthrenyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-46-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-
 octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl
 ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-55-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-methyl-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 419534-64-8 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(6-methyl-2-pyridinyl)-4b-(phenylmethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-87-5 CAPLUS

CN Carbamic acid, (2-amino-2-methylpropyl)-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-91-1 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-propyl-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-96-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-97-7 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419534-98-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-00-5 CAPLUS

CN Carbamic acid, [3-(diethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-01-6 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-02-7 CAPLUS

CN Carbamic acid, [3-(ethylmethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-03-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-04-9 CAPLUS

CN Carbamic acid, [2-(diethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-05-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(trifluoromethyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-07-2 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-24-3 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-26-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]methyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 419535-27-6 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]ethyl-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 419535-28-7 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-ethyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

03/18/2003

10006215.trn



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS

AB Compns. and methods are provided for achieving a therapeutic effect, including the treatment or prevention of syndrome X in an animal, preferably a mammal including a human subject or a companion animal, using a CRF antagonist alone or together with a glucocorticoid receptor antagonist.

ACCESSION NUMBER: 2001:338070 CAPLUS

DOCUMENT NUMBER: 134:336224

TITLE: Use of corticotropin releasing factor (CRF) antagonists for treating syndrome X

INVENTOR(S): Chen, Yuhpyng Liang; Hamanaka, Ernest Seiichi

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: Eur. Pat. Appl., 55 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1



PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1097709	A2	20010509	EP 2000-309441	20001026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
ZA 2000006008	A	20020426	ZA 2000-6008	20001026
PRIORITY APPLN. INFO.:		US 1999-162340P P 19991029		
OTHER SOURCE(S):		MARPAT 134:336224		
IT 305822-31-5				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(CRF antagonist, alone or with glucocorticoid receptor antagonist, for treating syndrome X)				
RN 305822-31-5 CAPLUS				
CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



L4 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2003 ACS
GI



AB Title compds. [e.g., I; D = CR7, CR7R16, N, NR7, O; E = C, CR6, N; F = CR4, CR4R5, O; R = XR1; R1 = H, alkyl, acylalkyl, arylalkyl, etc.; R2 = H, halo, alkyl, alkoxy, etc.; R3 = H, alkyl, arylalkyl, etc.; 1 of R2,R3 = null when adjacent dashed line = bond; R4,R5 = H, cyano, alkyl, alkoxy, etc.; R4R5 = O; R6 = H, cyano, alkyl, alkoxy, OH, etc.; R7,R16 = H, halo, cyano, alkyl, etc.; R7R16 = O; R8R9 = atoms to complete a substituted heteroarom. ring; R14,R15 = H, halo, alkyl, alkoxy, etc.; R14R15 = O when adjacent dashed lines = null; X = bond, CH2, CH(OH), CO; Z = (un)substituted CH2, -CH2CH2, -CH2CO, CO, etc.; dashed lines = optional bonds] were prepd. as glucocorticoid receptor modulators (no data). E.g., 6-methoxy-2-tetralone was alkylated by formation of the pyrrolidine enamine and alkylation with benzyl bromide; the benzylated ketone then undergoes asym. Michael addn. with Me vinyl ketone in the presence of (S)-(-)-.alpha.-methylbenzylamine followed by cyclocondensation with sodium methoxide to give a nonracemic methoxytetrahydrophenanthrenone deriv. E.g., demethylation of the methoxytetrahydrophenanthrenone with boron trichloride, redn. of the enone with lithium and ammonia, addn. of 1-lithiopropyne to the ketone, formation of the aryl triflate with triflic anhydride and carbonylation with carbon monoxide in the presence in the presence of palladium acetate and bis(diphenylphosphino)propanol gives an hydroxyoctahydrophenanthrenecarboxylic acid deriv. which is coupled with 4-(aminomethyl)pyridine in the presence of trimethylaluminum to give the octahydrophenanthrenecarboxamide II as one of the title compds.

ACCESSION NUMBER: 2000:790448 CAPLUS

DOCUMENT NUMBER: 133:350060

TITLE: Preparation of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors

INVENTOR(S): Dow, Robert Lee; Liu, Kevin Kun-Chin; Morgan, Bradley Paul; Swick, Andrew Gordon

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 279 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066522	A1	20001109	WO 2000-IB366	20000327
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000010138	A	20020122	BR 2000-10138	20000327
EP 1175383	A1	20020130	EP 2000-911172	20000327
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002543169	T2	20021217	JP 2000-615356	20000327
US 6380223	B1	20020430	US 2000-559384	20000427
NO 2001005272	A	20011228	NO 2001-5272	20011029
US 2002147336	A1	20021010	US 2002-80174	20020219
PRIORITY APPLN. INFO.:				
			US 1999-132130P	P 19990430
			WO 2000-IB366	W 20000327
			US 2000-559384	A3 20000427

OTHER SOURCE(S): MARPAT 133:350060

IT 305822-31-5P 305825-48-3P 305827-05-8P

305827-29-6P 305827-43-4P 305827-99-0P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305822-31-5 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 305825-48-3 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b-butyl-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl

ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-05-8 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,8aR)-4b-[[3-(dimethylamino)phenyl]methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-29-6 CAPLUS

CN Carbamic acid, [3-(dimethylamino)propyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 305827-43-4 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-(phenylmethyl)-7-(1-propynyl)-2-phenanthrenyl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 305827-99-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bR,7R,8aR)-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-4b-propyl-7-(1-propynyl)-2-phenanthrenyl ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



IT 305823-17-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of nonracemic octahydrophenanthrene and other tricyclic derivs. as selective modulators of glucocorticoid receptors)

RN 305823-17-0 CAPLUS

CN Carbamic acid, [2-(dimethylamino)ethyl]-, (4bS,7R,8aR)-4b-[[3-(dimethylamino)phenyl)methyl]-4b,5,6,7,8,8a,9,10-octahydro-7-hydroxy-7-(1-propynyl)-2-phenanthrenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

03/18/2003

10006215.trn

=> d his

(FILE 'HOME' ENTERED AT 11:54:19 ON 18 MAR 2003)

FILE 'REGISTRY' ENTERED AT 11:54:28 ON 18 MAR 2003

L1 STRUCTURE UPLOADED
L2 3 S L1
L3 28 S L1 FUL

FILE 'CAPLUS' ENTERED AT 11:55:34 ON 18 MAR 2003

L4 4 S L3

=> end

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
20.23	168.99

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-2.60	-2.60

CA SUBSCRIBER PRICE

STN INTERNATIONAL LOGOFF AT 11:58:42 ON 18 MAR 2003